Klaria Year-End Report 2023

Summary of the interim report

Fourth quarter of 2023

Remaining business operations

- Net sales 0.0 MSEK (2.2 MSEK)

- Other income 0.2 MSEK (0.2 MSEK)

- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)

- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)

- Earnings per share for the quarter amounted to -0.07 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)

Business operations for sale

- Profit after tax amounted to -1.6 MSEK

The period January–December 2023

Remaining business operations

- Net sales 0.0 MSEK (5.9 MSEK)

- Other income 0.2 MSEK (0.7 MSEK)

- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)

- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)

- Earnings per share for the period amounted to -0.18 SEK (-1.10 SEK)

- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)

Business operations for sale

- Profit after tax amounted to -17.4 MSEK

- Earnings per share for the quarter amounted to -0.17 SEK

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.